GANX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

GANX ▲ +4.23% at T+20d

NEUTRAL call ✓ call won +4.23% · α vs SPY -6.43% · entry $1.89 → $1.97

Next anchor: T+60d in 8d

Last close $1.68 (close Jun 12) · -11.11% from $1.89 entry

Entry anchored
Mar 25, 03:59 PM ET
via Databento tick

T+1d

-3.17%

call -3.17% · α -1.49%

$1.83

settled 3mo ago

T+5d

-2.12%

call -2.12% · α -3.75%

$1.85

settled 2mo ago

T+20d

+4.23%

call +4.23% · α -6.43%

$1.97

settled 7w ago

T+60d

—

call — · α —

—

in 8d

Price Chart

Loading chart...

Executive Summary

Gain Therapeutics reported financial results for 2025, showing a slight reduction in net loss to $20.2M from $20.4M in 2024, driven by lower R&D and G&A expenses. The company highlighted clinical progress with its lead candidate GT-02287 in Parkinson’s disease, including stable MDS-UPDRS scores and an 81% reduction in CSF GluSph levels, with Phase 1b extension data expected in 2026. Cash increased to $20.8M, supporting planned Phase 2 initiation in Q3 2026.

Key Financial Metrics

EPS

$-0.61

Actionable Insight

The improved cash position and reduced burn support near-term execution of the Phase 2 trial. Investors should monitor Q2 2026 for FDA IND feedback and Q4 2026 for full Phase 1b extension results, which could serve as a catalyst if they confirm disease-modifying effects.

Key Facts

Net loss decreased to $20.16M in 2025 from $20.41M in 2024, with EPS improving to -$0.61 from -$0.89.
R&D expenses declined by $0.6M to $10.2M, and G&A dropped by $1.1M to $8.5M, primarily due to lower stock-based compensation and legal fees.
Cash, cash equivalents, and marketable securities nearly doubled to $20.8M from $10.4M in 2024.
Phase 1b data for GT-02287 showed stable MDS-UPDRS scores and 81% reduction in CSF glucosylsphingosine (GluSph) in elevated-baseline patients after 90 days.
IND clearance for Phase 2 trial of GT-02287 expected in Q2 2026, with trial initiation anticipated in Q3 2026.

Financial Impact

Net loss reduced by $250K year-over-year; operating expenses down $1.64M. Cash position increased by $10.4M, providing runway into 2027.

net lossepscashr_and_d_expenseg_and_a_expense

Risk Factors

No revenue-generating products; company remains pre-revenue and dependent on capital markets.
Clinical development risk: GT-02287 is still early-stage, and Phase 2 may not replicate Phase 1b signals.
Foreign exchange exposure due to Swiss franc-denominated costs impacting expense volatility.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3262864

5 reports for GANX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for GANX — sortable, filterable
	Type				Now
May 26, 2026 19d ago	8-K BULLISH ★ 5/10	$1.82 $1.96	▲ +7.69%	▲ +6.61%	$1.68 (−7.69%)
May 11, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$1.82 $1.62	▼ −10.99%	▼ −10.90%	$1.68 (−7.69%)
Apr 28, 2026 6w ago	DEFA14A NEUTRAL ★ 3/10	$1.76 $1.91	▲ +8.52%	▲ +5.41%	$1.68 (−4.55%)
Mar 26, 2026 11w ago	Press Release MIXED ★ 6/10	$1.89 $1.85	▼ −2.12%	▼ −3.75%	$1.68 (−11.11%)
Mar 18, 2026 12w ago	Press Release BULLISH ★ 7/10	$1.95 $1.96	▲ +0.51%	▲ +1.23%	$1.68 (−13.85%)

US Market Status

Market Closed — Opens in 5h 3m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access